S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The 4th Military Revolution is Happening (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Closing prices for crude oil, gold and other commodities
Italian forces secure Turkish ship attacked by armed stowaways off Naples
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The 4th Military Revolution is Happening (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Closing prices for crude oil, gold and other commodities
Italian forces secure Turkish ship attacked by armed stowaways off Naples
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The 4th Military Revolution is Happening (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Closing prices for crude oil, gold and other commodities
Italian forces secure Turkish ship attacked by armed stowaways off Naples
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The 4th Military Revolution is Happening (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Closing prices for crude oil, gold and other commodities
Italian forces secure Turkish ship attacked by armed stowaways off Naples

ProPhase Labs (PRPH) Stock Forecast, Price & News

$8.08
-0.05 (-0.62%)
(As of 06/9/2023 ET)
Compare
Today's Range
$7.76
$8.25
50-Day Range
$7.50
$9.78
52-Week Range
$6.60
$15.25
Volume
105,295 shs
Average Volume
84,883 shs
Market Capitalization
$138.81 million
P/E Ratio
19.71
Dividend Yield
N/A
Price Target
$14.00

ProPhase Labs MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
73.3% Upside
$14.00 Price Target
Short Interest
Healthy
2.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.54mentions of ProPhase Labs in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.34) to $0.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

357th out of 988 stocks

Pharmaceutical Preparations Industry

164th out of 482 stocks


PRPH stock logo

About ProPhase Labs (NASDAQ:PRPH) Stock

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.

Receive PRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

PRPH Stock News Headlines

[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
H.C. Wainwright Remains a Buy on Prophase Labs (PRPH)
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Analyst Expectations for ProPhase Labs's Future
Recap: ProPhase Labs Q1 Earnings
7 Small-Cap Biotech Stocks with Massive Potential
See More Headlines

PRPH Price History

PRPH Company Calendar

Last Earnings
3/28/2023
Today
6/10/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRPH
Employees
95
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+73.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$18.46 million
Pretax Margin
8.01%

Debt

Sales & Book Value

Annual Sales
$122.65 million
Cash Flow
$1.44 per share
Book Value
$3.91 per share

Miscellaneous

Free Float
11,599,000
Market Cap
$138.81 million
Optionable
Not Optionable
Beta
-0.33

Key Executives

  • Ted William Karkus
    Chairman & Chief Executive Officer
  • Robert A. Morse
    Chief Financial & Accounting Officer













PRPH Stock - Frequently Asked Questions

Should I buy or sell ProPhase Labs stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRPH, but not buy additional shares or sell existing shares.
View PRPH analyst ratings
or view top-rated stocks.

What is ProPhase Labs' stock price forecast for 2023?

2 Wall Street analysts have issued 1-year target prices for ProPhase Labs' shares. Their PRPH share price forecasts range from $14.00 to $14.00. On average, they anticipate the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 73.3% from the stock's current price.
View analysts price targets for PRPH
or view top-rated stocks among Wall Street analysts.

How have PRPH shares performed in 2023?

ProPhase Labs' stock was trading at $9.63 at the beginning of the year. Since then, PRPH stock has decreased by 16.1% and is now trading at $8.08.
View the best growth stocks for 2023 here
.

When is ProPhase Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our PRPH earnings forecast
.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) posted its earnings results on Tuesday, March, 28th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.10. The firm earned $21.82 million during the quarter, compared to the consensus estimate of $20.53 million. ProPhase Labs had a net margin of 6.91% and a trailing twelve-month return on equity of 10.05%.

What ETF holds ProPhase Labs' stock ?

First Trust Dow Jones Select Microcap Index Fund holds 35,105 shares of PRPH stock, representing 0.18% of its portfolio.

What is Ted Karkus' approval rating as ProPhase Labs' CEO?

2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ProPhase Labs own?
What is ProPhase Labs' stock symbol?

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

Who are ProPhase Labs' major shareholders?

ProPhase Labs' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.12%), BlackRock Inc. (0.64%), Acadian Asset Management LLC (0.58%), American Century Companies Inc. (0.48%), Bank of New York Mellon Corp (0.38%) and State Street Corp (0.24%). Insiders that own company stock include Jason Michael Barr and Ted William Karkus.
View institutional ownership trends
.

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProPhase Labs' stock price today?

One share of PRPH stock can currently be purchased for approximately $8.08.

How much money does ProPhase Labs make?

ProPhase Labs (NASDAQ:PRPH) has a market capitalization of $138.81 million and generates $122.65 million in revenue each year. The company earns $18.46 million in net income (profit) each year or $0.41 on an earnings per share basis.

How can I contact ProPhase Labs?

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The official website for the company is www.prophaselabs.com. The company can be reached via phone at (215) 345-0919, via email at ir@prophaselabs.com, or via fax at 215-345-5920.

This page (NASDAQ:PRPH) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -